Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ferdi Sombogaard"'
Autor:
Selma En-nasery-de Heer, Jacqueline G. Hugtenburg, Pierre M. Bet, Bart J F van den Bemt, Patricia M. L. A. van den Bemt, Elien B. Uitvlugt, Ferdi Sombogaard, Fatma Karapinar-Çarkit
Publikováno v:
Research in Social and Administrative Pharmacy, 18(4), 2651-2658. ELSEVIER SCIENCE INC
Uitvlugt, E B, Heer, S E-N, van den Bemt, B J F, Bet, P M, Sombogaard, F, Hugtenburg, J G, van den Bemt, P M L A & Karapinar-Çarkit, F 2021, ' The effect of a transitional pharmaceutical care program on the occurrence of ADEs after discharge from hospital in patients with polypharmacy ', Research in Social and Administrative Pharmacy . https://doi.org/10.1016/j.sapharm.2021.05.009
Research in Social and Administrative Pharmacy. Elsevier Inc.
Research in Social & Administrative Pharmacy, 18, 2651-2658
Research in Social & Administrative Pharmacy, 18, 4, pp. 2651-2658
Research in Social and Administrative Pharmacy, 18(4), 2651-2658. Elsevier Inc.
Uitvlugt, E B, Heer, S E-N, van den Bemt, B J F, Bet, P M, Sombogaard, F, Hugtenburg, J G, van den Bemt, P M L A & Karapinar-Çarkit, F 2021, ' The effect of a transitional pharmaceutical care program on the occurrence of ADEs after discharge from hospital in patients with polypharmacy ', Research in Social and Administrative Pharmacy . https://doi.org/10.1016/j.sapharm.2021.05.009
Research in Social and Administrative Pharmacy. Elsevier Inc.
Research in Social & Administrative Pharmacy, 18, 2651-2658
Research in Social & Administrative Pharmacy, 18, 4, pp. 2651-2658
Research in Social and Administrative Pharmacy, 18(4), 2651-2658. Elsevier Inc.
Introduction: Transitional care programs (i.e. interventions delivered both in hospital and in primary care), could increase continuity and consequently quality of care. However, limited studies on the effect of these programs on Adverse Drug Events
Autor:
Marianne A. Kuijvenhoven, Sabrine Douiyeb, Kim C.E. Sigaloff, Ferdi Sombogaard, Jara R. de la Court, Tanca Minderhoud, Rogier P. Schade, Bram Tuinte
Publikováno v:
Douiyeb, S, de la Court, J R, Tuinte, B, Sombogaard, F, Schade, R P, Kuijvenhoven, M, Minderhoud, T & Sigaloff, K C E 2022, ' Risk factors for readmission among patients receiving outpatient parenteral antimicrobial therapy : a retrospective cohort study ', International Journal of Clinical Pharmacy, vol. 44, no. 2, pp. 557-563 . https://doi.org/10.1007/s11096-022-01379-7
International Journal of Clinical Pharmacy, 44(2), 557-563. Springer Netherlands
International Journal of Clinical Pharmacy, 44(2), 557-563. Springer Netherlands
Background: In the Netherlands, home treatment with intravenous antimicrobial therapy is a relatively new concept. Although several studies have shown that outpatient parenteral antimicrobial therapy (OPAT) can be administered safely, people receivin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29417a36744ac7de6a4507bd33a25034
https://doi.org/10.21203/rs.3.rs-1104099/v1
https://doi.org/10.21203/rs.3.rs-1104099/v1
Autor:
Sabrine Douiyeb, Jara R. de la Court, Bram Tuinte, Ferdi Sombogaard, Rogier P. Schade, Marianne Kuijvenhoven, Tanca Minderhoud, Kim C. E. Sigaloff
Publikováno v:
International Journal of Clinical Pharmacy. 44:834-834
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Autor:
Dennis A. Hesselink, Jiang Tao Tang, Teun van Gelder, Ferdi Sombogaard, Brenda C. M. de Winter, Lan Lan Wang
Publikováno v:
British Journal of Clinical Pharmacology, 83(4), 812-822. Wiley-Blackwell
Tang, J T, de Winter, B C, Hesselink, D A, Sombogaard, F, Wang, L L & van Gelder, T 2017, ' The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients ', British Journal of Clinical Pharmacology, vol. 83, no. 4, pp. 812-822 . https://doi.org/10.1111/bcp.13154
British Journal of Clinical Pharmacology, 83(4), 812-822. Wiley-Blackwell Publishing Ltd
Tang, J T, de Winter, B C, Hesselink, D A, Sombogaard, F, Wang, L L & van Gelder, T 2017, ' The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients ', British Journal of Clinical Pharmacology, vol. 83, no. 4, pp. 812-822 . https://doi.org/10.1111/bcp.13154
British Journal of Clinical Pharmacology, 83(4), 812-822. Wiley-Blackwell Publishing Ltd
Aims: Elderly transplant recipients have a lower incidence of acute rejection, and a higher risk to die from infectious complications. A potential cause may be differences in the pharmacokinetics (PK) or pharmacodynamics (PD) of the immunosuppressive
Publikováno v:
Pharmacogenetics Genomics, 23(12), 649-657. Lippincott Williams & Wilkins
BackgroundNew-onset diabetes after transplantation (NODAT) is an important complication after kidney transplantation. The etiology of the malady is multifactorial and includes both environmental and genetic factors. NODAT is a polygenic disease and m
Publikováno v:
Clinical Journal of the American Society of Nephrology, 6(3), 656-663. American Society of Nephrology
Clinical journal of the American Society of Nephrology, 6(3), 656-663. American Society of Nephrology
Clinical journal of the American Society of Nephrology, 6(3), 656-663. American Society of Nephrology
Background and objectives Mycophenolate mofetil (MMF) is an immunosuppressive drug used in renal transplant patients. Upon oral administration it is hydrolyzed to the active agent mycophenolic acid (MPA). In renal transplant recipients, MMF therapy i
Autor:
Teun van Gelder, Willem Weimar, Klemens Budde, Petra Glander, Ferdi Sombogaard, Laurent Essioux, Ron H.N. van Schaik, Marloes van der Werf, Arnold G. Vulto, Ron A. A. Mathôt
Publikováno v:
Pharmacogenetics Genomics, 19(8), 626-634. Lippincott Williams & Wilkins
Pharmacogenetics and genomics, 19(8), 626-634. Lippincott Williams and Wilkins
Pharmacogenetics and genomics, 19(8), 626-634. Lippincott Williams and Wilkins
Objectives The active metabolite of mycophenolate mofetil (MMF), mycophenolic acid, inhibits the activity of the target enzyme inosine monophosphate dehydrogenase (IMPDH). The aim of this study was to correlate eight different single nucleotide polym
Autor:
P. Hambach, Klemens Budde, Christine Lorkowski, Arnold G. Vulto, Marco Mai, Ron A. A. Mathôt, Petra Glander, Teun van Gelder, Hans H. Neumayer, Ferdi Sombogaard, Lutz Liefeldt
Publikováno v:
Therapeutic Drug Monitoring, 31(3), 351-359. Lippincott Williams & Wilkins
Therapeutic drug monitoring, 31(3), 351-359. Lippincott Williams and Wilkins
Therapeutic drug monitoring, 31(3), 351-359. Lippincott Williams and Wilkins
Mycophenolic acid (MPA) inhibits the enzyme inosine 5'-monophosphate dehydrogenase (IMPDH). Thus, the measurement of IMPDH activity could serve as a specific pharmacodynamic (PD) tool for monitoring MPA therapy. At present, however, monitoring of pha
Autor:
Leslie M. Shaw, Ron A. A. Mathot, Brenda C. M. de Winter, Reinier M. van Hest, Teun van Gelder, Ferdi Sombogaard
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics, 36(6), 541-564. Springer New York
Journal of Pharmacokinetics and Pharmacodynamics
Journal of Pharmacokinetics and Pharmacodynamics, 36(6), 541-564. Springer New York
Journal of Pharmacokinetics and Pharmacodynamics
Journal of Pharmacokinetics and Pharmacodynamics, 36(6), 541-564. Springer New York
Mycophenolic acid (MPA), the active compound of mycophenolate mofetil (MMF), is used to prevent graft rejection in renal transplant recipients. MPA is glucuronidated to the metabolite MPAG, which exhibits enterohepatic recirculation (EHC). MPA binds
Autor:
Annemiek M.A. Peeters, Willem Weimar, Arnold G. Vulto, Teun van Gelder, Ferdi Sombogaard, Carla C. Baan, Monique E. Quaedackers, Ron A. A. Mathôt
Publikováno v:
Therapeutic drug monitoring, 31(5), 549-556. Lippincott Williams and Wilkins
Therapeutic Drug Monitoring, 31(5), 549-556. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 31(5), 549-556. Lippincott Williams & Wilkins
Measurement of the pharmacodynamic biomarker inosine monophosphate dehydrogenase (IMPDH) activity in renal transplant recipients has been proposed to reflect the biological effect better than using pharmacokinetic parameters to monitor mycophenolate